Cwm LLC Acquires 33,656 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

CWM LLC increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 167.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 53,750 shares of the biotechnology company's stock after purchasing an additional 33,656 shares during the period. CWM LLC's holdings in BioCryst Pharmaceuticals were worth $403,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in BCRX. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $33,000. GAMMA Investing LLC boosted its position in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after buying an additional 5,449 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth $79,000. Raymond James Financial Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth $80,000. Finally, Syon Capital LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth $99,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, June 28th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Needham & Company LLC restated a "buy" rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock remained flat at $8.55 during trading on Friday. 2,363,782 shares of the stock traded hands, compared to its average volume of 3,191,850. The stock has a market cap of $1.79 billion, a P/E ratio of -32.88, a PEG ratio of 1.40 and a beta of 1.04. The stock's 50-day simple moving average is $9.80 and its 200 day simple moving average is $8.70. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.01 and a 1-year high of $11.31.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.